Intravenous injection of clinical grade human MSCs after experimental stroke: functional benefit and microvascular effect.

Intravenous injection of clinical grade human MSCs after experimental stroke: functional benefit and microvascular effect.
Cell Transplant. 2016 Feb 26;
Authors: Moisan A, Favre I, Rome C, De Fraipont F, Grillon E, Coquery N, Mathieu H, Mayan V, Naegele B, Hommel M, Richard MJ, Barbier EL, Remy C, Detante O
Abstract
Stroke is the leading cause of disability in adults. Many current clinical trials use an intravenous (IV) administration of human mesenchymal stromal/stem cells (hMSCs). This autologous graft requires a delay for ex vivo expansion of cells. We followed microvascular effects and mechanisms of action involved after an IV injection of hMSCs at a subacute phase of stroke. Rats underwent a transient middle cerebral artery occlusion (MCAo) or a surgery without occlusion (sham) at day 0 (D0). At D8, rats received an IV injection of 3 million hMSCs or PBSglutamine. In a longitudinal behavioral follow-up, we showed delayed somatosensory and cognitive benefits 4 to 7 weeks after hMSC injection. In a separate longitudinal in-vivo MRI study, we observed an enhanced vascular density in the ischemic area 2 and 3 weeks after hMSC injection. Histology and RT-qPCR enlighted an overexpression of angiogenic factors such as Ang1 and TGFß1 at D16 in hMSC-treated MCAo rats compared to PBS-treated MCAo rats. Altogether, delayed IV injection of hMSCs provides functional benefits and increases cerebral angiogenesis in the stroke lesion, via a re...

Source: Cell Transplantation - February 26, 2016 Category: Cytology Authors: Moisan A, Favre I, Rome C, De Fraipont F, Grillon E, Coquery N, Mathieu H, Mayan V, Naegele B, Hommel M, Richard MJ, Barbier EL, Remy C, Detante O Tags: Cell Transplant Source Type: research